Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $360.40 | Total: $1,802.00 |
| 1 | 10 | $305.28 | Total: $3,052.80 |
| 1 | 25 | $258.64 | Total: $6,466.00 |
| 1 | 50 | $220.48 | Total: $11,024.00 |
| 1 | 100 | $190.80 | Total: $19,080.01 |
Overview
Lestaurtinib (CEP 701) is an orally available and selective inhibitor of FMS-like tyrosine kinase-3 (FLT3, IC50: 0.9 nM), which inhibits FLT3 autophosphorylation in vitro.Lestaurtinib promotes the expression of c-MYC, inhibits the phosphorylation of RPTKs, and has high affinity for TrkA and JAK2. Lestaurtinib promotes c-MYC expression, inhibits phosphorylation of RPTKs, has a high affinity for TrkA and JAK2, induces apoptosis and cell growth arrest, and can be used to study leukemia.
Chemical Properties
| Molecular Formula | C26H21N3O4 |
| Molecular Weight | 439.46 |
| CAS Numbers | 111358-88-4 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C[C@]12N3C=4C=5N(C=6C(C5C7=C(C4C=8C3=CC=CC8)CNC7=O)=CC=CC6)[C@](O1)(C[C@@]2(CO)O)[H] |
Storage and Handling
0C Short Term, -20C Long Term
References
Miknyoczki SJ, et al. The novel Trk receptor tyrosine kinase inhibitor CEP-701 [KT-5555] exhibits antitumor efficacy against human pancreatic carcinoma [Panc1] xenograft growth and in vivo invasiveness. Ann N Y Acad Sci. 1999 Jun 30;880 252-62.